Imaging of Brain Receptors in Healthy Volunteers and in Patients With Schizophrenia
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Schizophrenia, SPECT, Nicotinic Acetylcholine Receptors, Cigarette Smoking, Cognitive Dysfunction, Reproducibility, Quantification, Healthy Volunteer, HV
Eligibility Criteria
INCLUSION CRITERIA: Controls-Group 1: Healthy Diagnosis; 21-80 years; No Cigarette Smoking; Plasma Cotinine less than 3 ng/mL; No olanzapine or risperidone Smoker Patients-Group 2: Diagnosis of Schizophrenia; 21-50 years; Cigarette Smoking greater than 20 per day and greater than 5 years; Plasma Cotinine greater than 100 ng/mL; Olanzapine or risperidone greater than 6 mo. and same dose for 2 weeks Non-Smoker Patients-Group 3: Diagnosis of Schizophrenia; 21-50 years; No Cigarette Smoking; Plasma Cotinine less than 3 ng/mL; Olanzapine or risperidone greater than 6 mo. and same dose for 2 weeks Smoker Controls-Group 4: Healthy Diagnosis; 21-50 years; Cigarette Smoking greater than 20 per day and greater than 5 years; Plasma Cotinine greater than 100 ng/mL; No olanzapine or risperidone Non-Smoker Controls-Group 5: Healthy Diagnosis; 21-50 years; No Cigarette Smoking; Plasma Cotinine less than 3 ng/mL; No olanzapine or risperidone
Sites / Locations
- National Institute of Mental Health (NIMH)